Myriad Genetics, Inc. (MYGN): Price and Financial Metrics

Myriad Genetics, Inc. (MYGN): $18.60

0.11 (+0.59%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

MYGN Price/Volume Stats

Current price $18.60 52-week high $24.21
Prev. close $18.49 52-week low $13.82
Day low $18.51 Volume 508,100
Day high $19.00 Avg. volume 623,567
50-day MA $21.39 Dividend yield N/A
200-day MA $19.22 Market Cap 1.68B

MYGN Stock Price Chart Interactive Chart >


Myriad Genetics, Inc. (MYGN) Company Bio


Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.


MYGN Latest News Stream


Event/Time News Detail
Loading, please wait...

MYGN Latest Social Stream


Loading social stream, please wait...

View Full MYGN Social Stream

Latest MYGN News From Around the Web

Below are the latest news stories about MYRIAD GENETICS INC that investors may wish to consider to help them evaluate MYGN as an investment opportunity.

Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) Anticipation

Piper Sandler initiated coverage on Myriad Genetics Inc (NASDAQ: MYGN), noting that many investors know the company as one of the earliest pioneers of genetic testing. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions. The company offers tests across multiple categories, including hereditary cancer, pharmacogenomics, and women’s health. It pioneered and was the market leader in BRCA testing for over ten y

Yahoo | December 21, 2023

Myriad Genetics' (MYGN) New Platform to Advance Cancer Care

Myriad Genetics' (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results.

Yahoo | December 21, 2023

Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

Scott Leffler Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief Financial Officer (CFO), effective January 29, 2024. Leffler will succeed Myriad CFO Bryan Riggsbee who is retiring. SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief Financial Officer (CFO), effective Ja

Yahoo | December 21, 2023

Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

The Myriad Collaborative Research Registry has more than one million patient casesSALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry™ (MCRR). Formerly known as the Precise Treatment Registry, the MCRR includes new data across germline and tumor testing results from Myriad’s cancer products on more than one million patients. The latest e

Yahoo | December 20, 2023

Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes

Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.

Yahoo | December 14, 2023

Read More 'MYGN' Stories Here

MYGN Price Returns

1-mo -16.37%
3-mo -13.73%
6-mo 30.89%
1-year -14.95%
3-year -38.21%
5-year -41.12%
YTD -2.82%
2023 31.91%
2022 -47.43%
2021 39.57%
2020 -27.38%
2019 -6.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!